Boundless Bio (BOLD) Treasury Shares (2023 - 2024)
Boundless Bio (BOLD) posted quarterly Treasury Shares of $287.4 million for Q1 2024, up 98.8% year-over-year from $144.6 million in Q2 2023, and little changed quarter-over-quarter from $287.4 million in Q4 2023.
Boundless Bio (BOLD) Treasury Shares (2023 - 2024) Analysis & Trends
Boundless Bio (BOLD) has reported Treasury Shares for 2 consecutive years, with $287.4 million the latest figure, recorded in Q1 2024.
- In Q1 2024, Treasury Shares rose 98.8% year-over-year to $287.4 million; the TTM figure through Mar 2024 stood at $287.4 million (up 98.8% YoY), while the FY2023 annual figure was $287.4 million, changed N/A from the prior year.
- Treasury Shares was little changed at $287.4 million in Q1 2024 per BOLD's latest filing, from $287.4 million in the prior quarter.
- Across five years, Treasury Shares topped out at $287.4 million in Q4 2023 and bottomed at $144.6 million in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 2.72 Mn |
| 10 | Boundless Bio | 66.79 Mn | 66.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 287.45 Mn |
| Mar 31, 2024 | 287.45 Mn |
| Dec 31, 2023 | 287.45 Mn |
| Dec 31, 2023 | 287.45 Mn |
| Sep 30, 2023 | 287.45 Mn |
| Sep 30, 2023 | 287.45 Mn |
| Jun 30, 2023 | 287.45 Mn |
| Jun 30, 2023 | 287.45 Mn |
| Mar 31, 2023 | 144.59 Mn |
| Mar 31, 2023 | 144.59 Mn |